# Hypoxia and aspirin additively increase intracellular glutamine accumulation in PIK3CA-mutated colorectal cancer cells

**Authors:** Nodoka Umezaki, Shogen Boku, Yoshiyuki Matsuo, Tetsushi Yamamoto, Hironaga Satake, Motoki Watanabe, Kiichi Hirota, Tomoharu Sugie, Mitsugu Sekimoto

PMC · DOI: 10.1038/s41598-026-42753-z · 2026-03-24

## TL;DR

Aspirin and hypoxia together increase glutamine in PIK3CA-mutated colorectal cancer cells, suggesting a new way to improve aspirin's cancer-fighting effects.

## Contribution

The study reveals that aspirin and hypoxia synergistically boost glutamine levels in PIK3CA-mutated colorectal cancer cells.

## Key findings

- Aspirin and hypoxia additively increase intracellular glutamine in PIK3CA-mutated cells.
- Blocking glutamine transport with V-9302 reverses this effect and shows antitumor potential.
- Aspirin's effects are linked to amino acid metabolism and hypoxic pathways in these cells.

## Abstract

Aspirin exhibits potential as a repurposed agent for preventing and treating cancer, specifically PIK3CA-mutated (MT) colorectal cancer. However, the fundamental biological reasons for the particular antitumor activity of aspirin against PIK3CA-MT colorectal cancer are not yet fully elucidated. We have previously established that aspirin relates to glutamine metabolism in PIK3CA-MT colorectal cancer. In evaluating the antitumor effects of aspirin, it is essential to consider the tumor growth environment, such as hypoxia. The impact of the tumor microenvironment on aspirin efficacy remains unknown. Therefore, we aimed to investigate the mechanisms through which hypoxia influences aspirin- associated intracellular glutamine accumulation in PIK3CA-MT colorectal cancer cell lines. Connectivity Map analysis was used to explore the associations of aspirin with biological pathways in HT-29 (PIK3CA-MT) cells. RNA sequencing was performed on PIK3CA-wild type (WT)/mutant isogenic SW48 cell lines to assess aspirin’s effects under hypoxic conditions. Targeted metabolomics was employed to measure intracellular glutamine levels in PIK3CA-MT HCT116 cells following aspirin treatment and hypoxic stimulation. Bioinformatic analysis revealed associations of aspirin with amino acid metabolism and hypoxic pathways. Under hypoxic conditions, aspirin enhanced amino acid uptake in PIK3CA-MT cells. Targeted metabolomics showed that aspirin treatment and hypoxic stimulation additively upregulated intracellular glutamine levels in PIK3CA-MT cells. This increase was reversed by V-9302, an inhibitor of the glutamine transporter ASCT2, which demonstrated antitumor potential in combination with aspirin. Our findings suggest that the combination of aspirin and hypoxia significantly enhances intracellular glutamine accumulation in PIK3CA-MT colorectal cancer under hypoxic conditions, emphasizing glutamine metabolism as a potential therapeutic target to enhance aspirin’s efficacy.

The online version contains supplementary material available at 10.1038/s41598-026-42753-z.

## Linked entities

- **Genes:** PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) [NCBI Gene 5290]
- **Chemicals:** aspirin (PubChem CID 2244), V-9302 (PubChem CID 127035871)
- **Diseases:** colorectal cancer (MONDO:0005575)

## Full-text entities

- **Genes:** MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, PTGS2 (prostaglandin-endoperoxide synthase 2) [NCBI Gene 5743] {aka COX-2, COX2, GRIPGHS, PGG/HS, PGHS-2, PHS-2}, GLUL (glutamate-ammonia ligase) [NCBI Gene 2752] {aka DEE116, GLNS, GS, PIG43, PIG59}, GLS (glutaminase) [NCBI Gene 2744] {aka AAD20, CASGID, DEE71, EIEE71, GAC, GAM}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, SLC1A5 (solute carrier family 1 member 5) [NCBI Gene 6510] {aka AAAT, ASCT2, ATBO, M7V1, M7VS1, R16}, APC (APC regulator of Wnt signaling pathway) [NCBI Gene 324] {aka BTPS2, DESMD, DP2, DP2.5, DP3, GS}, KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845] {aka 'C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A}, COX5A (cytochrome c oxidase subunit 5A) [NCBI Gene 9377] {aka COX, COX-VA, MC4DN20, VA}, GLUD1 (glutamate dehydrogenase 1) [NCBI Gene 2746] {aka GDH, GDH1, GLUD, hGDH1}, PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) [NCBI Gene 5290] {aka CCM4, CLAPO, CLOVE, CWS5, HMH, MCAP}, COX1 (cytochrome c oxidase subunit I) [NCBI Gene 4512] {aka COI, MTCO1}, COX2 (cytochrome c oxidase subunit II) [NCBI Gene 4513] {aka COII, MTCO2}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}
- **Diseases:** malignant melanoma (MESH:D008545), Hypoxia (MESH:D000860), cancer (MESH:D009369), breast cancer (MESH:D001943), Hypoxic (MESH:D002534), hematological and solid tumors (MESH:D019337), prostate cancer (MESH:D011471), lung cancer (MESH:D008175), tumorigenesis (MESH:D063646), CRC (MESH:D015179), hematologic (MESH:D006402)
- **Chemicals:** formalin (MESH:D005557), ROS (MESH:D017382), methanol (MESH:D000432), DMSO (MESH:D004121), glutamate (MESH:D018698), H2O2 (MESH:D006861), penicillin (MESH:D010406), ammonium hydroxide (MESH:D064753), Amino acid (MESH:D000596), PBS (MESH:D007854), ASA (MESH:D001241), L (MESH:D007930), cysteine (MESH:D003545), glutathione (MESH:D005978), acetyl-CoA (MESH:D000105), PGE2 (MESH:D015232), NO (MESH:D009614), CO2 (MESH:D002245), water (MESH:D014867), glucose (MESH:D005947), formic acid (MESH:C030544), nucleotide (MESH:D009711), CB-839 (MESH:C000593334), streptomycin (MESH:D013307), WST-8 (MESH:C476329), ROS-Glo (-), Poly(A) (MESH:D011061), TCA (MESH:D014233), luciferin (MESH:D000090562), lactate (MESH:D019344), crystal violet (MESH:D005840), O2 (MESH:D010100), Glutamine (MESH:D005973), chloroform (MESH:D002725), phenol red (MESH:D010637), prostacyclin (MESH:D011464), CCK-8 (MESH:D012844), NADPH (MESH:D009249)
- **Species:** Mycoplasma (genus) [taxon 2093], Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** E545K, H1047R, glutamine to glutamate
- **Cell lines:** VCaP — Homo sapiens (Human), Prostate carcinoma, Cancer cell line (CVCL_2235), PC3 — Homo sapiens (Human), Prostate carcinoma, Cancer cell line (CVCL_0035), DLD-1 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0248), A549 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_0023), MT — Homo sapiens (Human), Chronic myelogenous leukemia, BCR-ABL1 positive, Cancer cell line (CVCL_TD61), HA1E — Homo sapiens (Human), Transformed cell line (CVCL_VU89), MCF-7 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0031), HCT116 — Homo sapiens (Human), Colon carcinoma, Cancer cell line (CVCL_0291), HCC515 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_5136), SW48 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_1724), A375 — Homo sapiens (Human), Amelanotic melanoma, Cancer cell line (CVCL_0132), HT-29 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0320)

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13013922/full.md

---
Source: https://tomesphere.com/paper/PMC13013922